5-Bromotetrandrine enhances the sensitivity of doxorubicin-induced apoptosis in intrinsic resistant human hepatic cancer Bel7402 cells

Cancer Letters

Volumn 292, Issue 1, 2010, Pages 24-31

  Liu, Xiao Dong ^a   Sun, Hua ^a   Liu, Geng Tao ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

5 Bromotetrandrine; Apoptosis; Bax Bcl 2; Mitochondrial transmembrane potential; Multi drug resistance

Indexed keywords

5 BROMOTETRANDRINE; APOPTOSIS INDUCING FACTOR; BISBENZYLISOQUINOLINE ALKALOID; CASPASE 3; CASPASE 8; CYTOCHROME C; DOXORUBICIN; FAS LIGAND; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; VERAPAMIL; BENZYLISOQUINOLINE DERIVATIVE; BROMOTETRANDRINE; DEATH RECEPTOR;

APOPTOSIS; ARTICLE; CHROMATIN CONDENSATION; CONTROLLED STUDY; CYTOSOL; DNA FRAGMENTATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; BIOSYNTHESIS; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; LIVER TUMOR; METABOLISM; MULTIDRUG RESISTANCE; TUMOR CELL LINE;

APOPTOSIS; BENZYLISOQUINOLINES; CASPASE 3; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; LIVER NEOPLASMS; RECEPTORS, DEATH DOMAIN; VERAPAMIL;

EID: 77951233314     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.11.001     Document Type: Article

References (32)

1. Mimeault M., Brand R.E., Sasson A.A., Batra S.K. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 2005, 31:301-316.
2. Mimeault M., Batra S.K. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006, 27:1-22.
3. Lock-Andersen J., Horn J., Sjostrand H. Prognosis after sentinel node biopsy in malignant melanoma. Ugeskrift Laeger 2006, 168:2457-2462.
4. Nicum S., Midgley R., Kerr D.J. Colorectal cancer. Acta Oncol. 2003, 42:263-275.
5. Shabbits J.A., Hu Y., Mayer L.D. Tumor chemosensitization strategies based on apoptosis manipulations. Mol. Cancer Ther. 2003, 2:805-813.
6. Mimeault M., Hauke R., Batra S.K. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin. Pharmacol. Ther. 2008, 83:673-691.
7. Debatin K.M., Poncet D., Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 2002, 21:8786-8803.
8. Norbury C.J., Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004, 23:2797-2808.
9. Ferreira C.G., Epping M., Kruyt F.A., Giaccone G. Apoptosis: target of cancer therapy. Clin. Cancer Res. 2002, 8:2024-2034.
10. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2:277-288.
11. Eberle J., Kurbanov B.M., Hossini A.M., Trefzer U., Fecker L.F. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist. Update 2007, 10:218-234.
12. Eberle J., Fecker L.F., Forschner T., Ulrich C., Rowert-Huber J., Stockfleth E. Apoptosis pathways as promising targets for skin cancer therapy. Brit. J. Dermatol. 2007, 156(Suppl. 3):18-24.
13. Schimmer A.D. Novel therapies targeting the apoptosis pathway for the treatment of acute myeloid leukemia. Curr. Treat. Options Oncol. 2007, 8:277-286.
14. Bedikian A.Y., Millward M., Pehamberger H., Conry R., Gore M., Trefzer U., Pavlick A.C., DeConti R., Hersh E.M., Hersey P., Kirkwood J.M., Haluska F.G. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 2006, 24:4738-4745.
15. Jin J., Wang F.P., Wei H., Liu G. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother. Pharmacol. 2005, 55:179-188.
16. Jacobson M.D., Weil M., Raff M.C. Programmed cell death in animal development. Cell 1997, 88:347-354.
17. Fan T.J., Han L.H., Cong R.S., Liang J. Caspase family proteases and apoptosis. Acta Biochim. Biophys. Sin. (Shanghai) 2005, 37:719-727.
18. Rao R.V., Ellerby H.M., Bredesen D.E. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ. 2004, 11:372-380.
19. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
20. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
21. Henry-Mowatt J., Dive C., Martinou J.C., James D. Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene 2004, 23:2850-2860.
22. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat. Med. 2000, 6:513-519.
23. Jacotot E., Costantini P., Laboureau E., Zamzami N., Susin S.A., Kroemer G. Mitochondrial membrane permeabilization during the apoptotic process. Ann. NY Acad. Sci. 1999, 887:18-30.
24. Ly J.D., Grubb D.R., Lawen A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis 2003, 8:115-128.
25. Green D.R., Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004, 305:626-629.
26. Zamzami N., Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat. Rev. Mol. Cell Biol. 2001, 2:67-71.
27. Liu H., Qin C.K., Han G.Q., Xu H.W., Ren W.H., Qin C.Y. Synthetic chenodeoxycholic acid derivative, HS-1200, induces apoptosis of human hepatoma cells via a mitochondrial pathway. Cancer Lett. 2008, 270:242-249.
28. Arisan E.D., Kutuk O., Tezil T., Bodur C., Telci D., Basaga H. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. Breast Cancer Res. Treat. 2009.
29. Korynevska A., Heffeter P., Matselyukh B., Elbling L., Micksche M., Stoika R., Berger W. Mechanisms underlying the anticancer activities of the angucycline landomycin E. Biochem. Pharmacol. 2007, 74:1713-1726.
30. Ong R.C., Lei J., Lee R.K., Cheung J.Y., Fung K.P., Lin C., Ho H.P., Yu B., Li M., Kong S.K. Polyphyllin D induces mitochondrial fragmentation and acts directly on the mitochondria to induce apoptosis in drug-resistant HepG2 cells. Cancer Lett. 2008, 261:158-164.
31. Shi Z., Peng X.X., Kim I.W., Shukla S., Si Q.S., Robey R.W., Bates S.E., Shen T., Ashby C.R., Fu L.W., Ambudkar S.V., Chen Z.S., (Tarceva Erlotinib OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 2007, 67:11012-11020.
32. Tiwari A.K., Sodani K., Wang S.R., Kuang Y.H., Ashby C.R., Chen X., Chen Z.S. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem. Pharmacol. 2009, 78:153-161.